Advanced search

Find pages with...
Then narrow your results by...

About 77 search results

Health Products that May Pose a Serious Risk to Health Removed From Vancouver Island Stores

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2010/13452a-eng.php

Feb 1, 2013 .... Reason The labels on some of these products indicate they contain ingredients that legally require the products to be sold by prescription because they are used to treat serious diseases or may have side effects that require monitoring by a health care practitioner. What you should do Consult your healthcare practitioner if you have used any of these products

Recall of All Lots of Sandoz Timolol Ophthalmic Solution (Timolol Maleate Ophthalmic Solution USP) 0.25% and 0.5% - For Health Professionals

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2008/14523a-eng.php

Mar 5, 2013 ... 8550, 8560, 8570, 8580, 8590 and 8600) because certain bottles from different lots of these products were found to contain a higher concentration of timolol than the approved labelled specifications. By using the solution at a higher concentration, the maximum recommended dosage of 1 drop twice daily of 0.5% may be exceeded. The possible adverse effects

Association of Bextra (Valdecoxib) with Serious Adverse Drug Reactions – Pfizer Canada Inc. – For Health Professionals

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2005/14311a-eng.php

Jun 3, 2013 ... Medicines Agency (EMEA). Furthermore, in the U.S., on 7 April 2005, FDA announced a series of important changes pertaining to the labeling and marketing of the NSAID group of drugs including COX-2 inhibitors. Advice to Health Care Professionals Prescribers are advised: Not to initiate treatment of new patients To switch patients to alternative therapy where

NON-VENTED DISPENSING PIN (2016-04-14)

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58362r-eng.php

..., Hospitals Identification number: RA-58362 Reason Affected products Affected products NON-VENTED DISPENSING PIN Reason B. Braun Medical Inc. has identified a potential for a tear in the outer blister packaging on a limited number of units. The tears have been identified in the blister package paper, where the unit label writing is located. A tear results

Health Canada updates prescribing and dispensing information for Mifegymiso

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/65034a-eng.php

... with Celopharma in order to prescribe or dispense Mifegymiso. The formulation of Mifegymiso itself has not changed. It remains a combination product containing two medications: mifepristone and misoprostol. These medications are used in sequence for the medical termination of a pregnancy. The changes being announced today apply only to use and product labelling. Health

Health Canada Releases Important Information on the Dispensation of CLOZAPINE Products in Canada – Notice to Hospitals

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2004/14250a-eng.php

.... These revisions will strengthen the labeling and address ongoing issues around patient consent for the sharing of information between registries, considered important due to the well-known risk of agranulocytosis associated with clozapine use. Revisions to clozapine Product Monographs will emphasize the following: the switching of a patient from one brand of clozapine

Alesse 21 and 28 birth control pill: Packages may contain broken or smaller-than-normal pills, which may reduce effectiveness in preventing pregnancy

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/65306a-eng.php

...Alesse 21 and 28 birth control pill: Packages may contain broken or smaller-than-normal pills, which may reduce effectiveness in preventing pregnancy Report a Concern Starting date: December 1, 2017 Type of communication: Advisory Subcategory: Drugs Source of recall: Health Canada Issue: Important Safety Information, Labelling and Packaging Audience

Search results

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/search-recherche/simple?js_en=&page=1000&per_page=24000&plain_text=&s=

Mar 30, 2012 ... issued a recall on the ALLSTARSTARLITE,STARQUEST, and XLT models STARCRAFT BUS AND MOBILITY issued a recall on the ALLSTARSTARLITE,STARQUEST, and XLT models Certain vehicles do not comply with the requirements of CMVSS 217. The rear door is not labelled correctly to identify that it is an emergency exit and instructions for opening the door are not affixed

Health Canada releases important information on the dispensation of CLOZAPINE products in Canada - For Health Professionals

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2004/14249a-eng.php

... Directorate (MHPD) and the Therapeutic Products Directorate (TPD) would like to draw your attention to important upcoming revisions to the Product Monographs of all clozapine products marketed in Canada. These revisions will strengthen the labelling and address ongoing issues around patient consent for the sharing of information between registries. As you know

Pulmicort Turbuhaler (budesonide) powder for oral inhalation - Potential device failure - For Health Professionals

https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/15087a-eng.php

..., or visit the MedEffect™ Canada Web site for information on how to report. The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties. For other health product inquiries related

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: